Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Acid blockers may complicate pancreatic necrosis recovery, new trial investigates

NCT ID NCT07488299

Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study looks at whether giving patients acid-reducing drugs (proton pump inhibitors) after an endoscopic procedure to drain pancreatic walled-off necrosis affects how many additional procedures they need. About 120 adults with this condition will be randomly assigned to receive the drug or not. The goal is to see if the drug increases the number of treatments needed and impacts complications, hospital stay, and costs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 18 years or older and not exceeding 80 years of age. 2. Patients with a confirmed diagnosis of WON. 3. Patients requiring endoscopic ultrasound-guided transluminal drainage/debridement therapy. 4. Patients who have signed informed consent forms. Exclusion Criteria: 1. Patients diagnosed with chronic pancreatitis who have not experienced an acute pancreatitis attack within the past three months. 2. Patients with severe coagulation disorders (International Normalized Ratio \[INR\] \> 1.5). 3. Patients with significant thrombocytopenia (platelet count \< 50 × 10\^9/L). 4. Pregnant women. 5. Patients undergoing endoscopic drainage solely through the duodenum. 6. Patients with a history of gastrectomy, gastric bypass surgery, or prior surgery for pancreatic-related diseases. 7. Patients currently taking medications that may affect gastric acid secretion or metabolism, such as strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., clarithromycin, itraconazole) or inducers (e.g., rifampin, carbamazepine). 8. Patients requiring long-term use of acid-suppressing medications such as PPIs and P-CABs due to other medical conditions. 9. Patients with a history of acid-suppressive medication use (e.g., PPI) and a washout period of less than 14 days. 10. Patients with documented contraindications to PPIs or a relevant history of hypersensitivity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic walled-off necrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic walled-off necrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, Shandong, 250063, China